Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.

Renamezin® is a modified capsule-type oral spherical adsorptive carbon which lowers indoxyl sulfate levels in patients with advanced chronic kidney disease (CKD). This 24-week prospective observational cohort study was performed to evaluate the effect of Renamezin® upon attenuation of renal function...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hayne Cho Park, AJin Cho, Do Hyoung Kim, Kyu-Sang Yun, Juhee Kim, Eun Young Lee, Sang Kyung Jo, So-Young Lee, Kum Hyun Han, Yoon Kyung Chang, Dong-Jin Oh, Young-Ki Lee
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e43a856dfa6443f19dbe8384cfe09544
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e43a856dfa6443f19dbe8384cfe09544
record_format	dspace
spelling	oai:doaj.org-article:e43a856dfa6443f19dbe8384cfe095442021-12-02T20:03:55ZEffect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.1932-620310.1371/journal.pone.0252186https://doaj.org/article/e43a856dfa6443f19dbe8384cfe095442021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252186https://doaj.org/toc/1932-6203Renamezin® is a modified capsule-type oral spherical adsorptive carbon which lowers indoxyl sulfate levels in patients with advanced chronic kidney disease (CKD). This 24-week prospective observational cohort study was performed to evaluate the effect of Renamezin® upon attenuation of renal function decline. A total of 1,149 adult patients with baseline serum creatinine 2.0-5.0 mg/dL were enrolled from 22 tertiary hospital in Korea from April 2016 to September 2018. Among them, a total of 686 patients completed the study and were included in the intention-to-treat analysis. A total of 1,061 patients were included in the safety analysis. The mean age was 63.5 years and male patients were predominant (63.6%). Most of the patients (76.8%) demonstrated high compliance with study drug (6g per day). After 24 week of treatment, serum creatinine was increased from 2.86±0.72 mg/dL to 3.06±1.15 mg/dL (p<0.001), but estimated glomerular filtration rate was not changed significantly during observation period (22.3±6.8 mL/min/1.73m2 to 22.1±9.1 mL/min/1.73m2, p = 0.243). Patients with age over 65 years old and those under good systolic blood pressure control <130 mmHg were most likely to get benefit from Renamezin® treatment to preserve renal function. A total of 98 (9.2%) patients out of 1,061 safety population experienced 134 adverse events, of which gastrointestinal disorders were the most common. There were no serious treatment-related adverse events. Renamezin® can be used safely to attenuate renal function decline in moderately advanced CKD patients.Hayne Cho ParkAJin ChoDo Hyoung KimKyu-Sang YunJuhee KimEun Young LeeSang Kyung JoSo-Young LeeKum Hyun HanYoon Kyung ChangDong-Jin OhYoung-Ki LeePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0252186 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hayne Cho Park AJin Cho Do Hyoung Kim Kyu-Sang Yun Juhee Kim Eun Young Lee Sang Kyung Jo So-Young Lee Kum Hyun Han Yoon Kyung Chang Dong-Jin Oh Young-Ki Lee Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
description	Renamezin® is a modified capsule-type oral spherical adsorptive carbon which lowers indoxyl sulfate levels in patients with advanced chronic kidney disease (CKD). This 24-week prospective observational cohort study was performed to evaluate the effect of Renamezin® upon attenuation of renal function decline. A total of 1,149 adult patients with baseline serum creatinine 2.0-5.0 mg/dL were enrolled from 22 tertiary hospital in Korea from April 2016 to September 2018. Among them, a total of 686 patients completed the study and were included in the intention-to-treat analysis. A total of 1,061 patients were included in the safety analysis. The mean age was 63.5 years and male patients were predominant (63.6%). Most of the patients (76.8%) demonstrated high compliance with study drug (6g per day). After 24 week of treatment, serum creatinine was increased from 2.86±0.72 mg/dL to 3.06±1.15 mg/dL (p<0.001), but estimated glomerular filtration rate was not changed significantly during observation period (22.3±6.8 mL/min/1.73m2 to 22.1±9.1 mL/min/1.73m2, p = 0.243). Patients with age over 65 years old and those under good systolic blood pressure control <130 mmHg were most likely to get benefit from Renamezin® treatment to preserve renal function. A total of 98 (9.2%) patients out of 1,061 safety population experienced 134 adverse events, of which gastrointestinal disorders were the most common. There were no serious treatment-related adverse events. Renamezin® can be used safely to attenuate renal function decline in moderately advanced CKD patients.
format	article
author	Hayne Cho Park AJin Cho Do Hyoung Kim Kyu-Sang Yun Juhee Kim Eun Young Lee Sang Kyung Jo So-Young Lee Kum Hyun Han Yoon Kyung Chang Dong-Jin Oh Young-Ki Lee
author_facet	Hayne Cho Park AJin Cho Do Hyoung Kim Kyu-Sang Yun Juhee Kim Eun Young Lee Sang Kyung Jo So-Young Lee Kum Hyun Han Yoon Kyung Chang Dong-Jin Oh Young-Ki Lee
author_sort	Hayne Cho Park
title	Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
title_short	Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
title_full	Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
title_fullStr	Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
title_full_unstemmed	Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
title_sort	effect of renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/e43a856dfa6443f19dbe8384cfe09544
work_keys_str_mv	AT haynechopark effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT ajincho effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT dohyoungkim effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT kyusangyun effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT juheekim effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT eunyounglee effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT sangkyungjo effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT soyounglee effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT kumhyunhan effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT yoonkyungchang effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT dongjinoh effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy AT youngkilee effectofrenamezinuponattenuationofrenalfunctiondeclineinpredialysischronickidneydiseasepatients24weekprospectiveobservationalcohortstudy
_version_	1718375635367231488

Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.

Ejemplares similares